Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Guggulsterone SCHEMBL7860363 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL14193742 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL1650063 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12153588 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL13304392 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL13327483 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12858540 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177786 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL258031 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| Guggulsterone SCHEMBL141657 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360673-A1 | HAIR COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2017-12-21 | — | — | US | claimed |
| EP-3236927-A1 | HAIR COMPOSITION | Unilever PLC (GB) | 2017-11-01 | — | — | EP | claimed |
| WO-2016102177-A1 | HAIR COMPOSITION | UNILEVER PLC (GB) | 2016-06-30 | — | — | WO | claimed |
| EP-2788088-A1 | SKIN ANTI-AGEING COMPOSITION | Unilever Plc. (GB) | 2014-10-15 | — | — | EP | claimed |
| US-20140295010-A1 | SKIN ANTI-AGEING COMPOSITION | CONOPCO, INC. D/B/A UNILEVER (US) | 2014-10-02 | — | — | US | claimed |
| US-8647643-B2 | Farnesoid-X-receptor antagonist as a vaccine adjuvant | CADILA PHARMACEUTICALS, LTD (IN) | 2014-02-11 | — | — | US | claimed |
| WO-2013083431-A1 | SKIN ANTI-AGEING COMPOSITION | UNILEVER PLC (GB) | 2013-06-13 | — | — | WO | claimed |
| WO-2011073440-A3 | DEODORANT COMPOSITION BASED ON ANTIMICROBIAL PEPTIDES AND METHOD FOR TREATING BODY ODOUR | L'OREAL (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-1620455-B1 | PROCESS FOR PREPARING GUGGULSTERONES AND GUGGULSTEROL | SEOUL NAT UNIV IND FOUNDATION (KR) | 2011-11-30 | — | — | EP | claimed |
| US-20110182939-A1 | Vaccine Adjuvants | CADILA PHARMACEUTICALS LTD. (IN) | 2011-07-28 | — | — | US | claimed |
| EP-2337847-A2 | VACCINE ADJUVANTS | Cadila Pharmaceuticals Ltd. (IN) | 2011-06-29 | — | — | EP | claimed |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-08 | — | — | US | claimed |
| WO-2010035119-A2 | VACCINE ADJUVANTS | CADILA PHARMACEUTICALS LTD. (IN) | 2010-04-01 | — | — | WO | claimed |
| EP-1886685-A1 | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-02-13 | — | — | EP | claimed |
| EP-1627030-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2006-02-22 | — | — | EP | claimed |
| WO-2004104143-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2004103376-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | claimed |
| EP-1432399-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2004-06-30 | — | — | EP | claimed |
| WO-2003030857-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2003-04-17 | — | — | WO | claimed |
| EP-3514246-B1 | T CELL BALANCE GENE EXPRESSION AND METHODS OF USE THEREOF | BROAD INST INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10870885-B2 | Dendritic cell response gene expression, compositions of matters and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2020235967-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING AUTOIMMUNE DISEASES | 연세대학교 산학협력단 (KR) | 2020-11-26 | — | — | WO | disclosed |
| US-10822587-B2 | T cell balance gene expression, compositions of matters and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200081017-A1 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-03-12 | — | — | US | disclosed |
| US-10456344-B2 | Hair composition | CONOPCO, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10406091-B2 | Skin anti-ageing composition | CONOPCO, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3514246-A1 | T CELL BALANCE GENE EXPRESSION AND METHODS OF USE THEREOF | The Broad Institute Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-2788088-B1 | SKIN ANTI-AGEING COMPOSITION | UNILEVER PLC (GB) | 2019-06-19 | — | — | EP | disclosed |
| EP-3110971-B1 | T CELL BALANCE GENE EXPRESSION AND METHODS OF USE THEREOF | BROAD INST INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10258632-B2 | Method of prevention of neurological diseases | INTERNATIONAL STEM CELL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170360673-A1 | HAIR COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3236927-A1 | HAIR COMPOSITION | Unilever PLC (GB) | 2017-11-01 | — | — | EP | disclosed |
| EP-3110971-A2 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016102177-A1 | HAIR COMPOSITION | UNILEVER PLC (GB) | 2016-06-30 | — | — | WO | disclosed |
| EP-2971116-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2961849-A2 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150368719-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150361396-A1 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2015-12-17 | — | — | US | disclosed |
| EP-2337847-B1 | VACCINE ADJUVANTS | CADILA PHARMACEUTICALS LTD (IN) | 2015-12-02 | — | — | EP | disclosed |
| WO-2015130968-A2 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute Inc. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150094289-A1 | Method of Prevention of Neurological Diseases | INTERNATIONAL STEM CELL CORPORATION | 2015-04-02 | — | — | US | disclosed |
| EP-2841060-A1 | METHOD OF PREVENTION OF NEUROLOGICAL DISEASES | International Stem Cell Corporation (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2788088-A1 | SKIN ANTI-AGEING COMPOSITION | Unilever Plc. (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-20140295010-A1 | SKIN ANTI-AGEING COMPOSITION | CONOPCO, INC. D/B/A UNILEVER (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014145631-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014134351-A2 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-8647643-B2 | Farnesoid-X-receptor antagonist as a vaccine adjuvant | CADILA PHARMACEUTICALS, LTD (IN) | 2014-02-11 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013184591-A1 | METHOD OF PREVENTION OF NEUROLOGICAL DISEASES | INTERNATIONAL STEM CELL CORPORATION (US) | 2013-12-12 | — | — | WO | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013083431-A1 | SKIN ANTI-AGEING COMPOSITION | UNILEVER PLC (GB) | 2013-06-13 | — | — | WO | disclosed |
| EP-2594577-A1 | Process for preparing guggulsterones and guggulsterol | Seoul National University Industry Foundation (KR) | 2013-05-22 | — | — | EP | disclosed |
| US-8318710-B2 | Skin treatments | CONOPCO, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011073440-A3 | DEODORANT COMPOSITION BASED ON ANTIMICROBIAL PEPTIDES AND METHOD FOR TREATING BODY ODOUR | L'OREAL (FR) | 2012-05-10 | — | — | WO | disclosed |
| EP-2399575-A2 | Methods, uses and compositions for treatment of an infection by a virus of the family of flaviviridae through the farnesoid X receptor (FXR) inhibition | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399988-A2 | Cell culture system for replication of HCV through the farnesoid X receptor (FXR) activation or inhibition and diagnostic method for HCV infection | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-12-28 | — | — | EP | disclosed |
| EP-1620455-B1 | PROCESS FOR PREPARING GUGGULSTERONES AND GUGGULSTEROL | SEOUL NAT UNIV IND FOUNDATION (KR) | 2011-11-30 | — | — | EP | disclosed |
| JP-2011157382-A | METHOD FOR PRODUCING GUGGULSTERONE AND GUGGULSTEROL | SEOUL NATIONAL UNIV INDUSTRY FOUNDATION | 2011-08-18 | — | — | JP | disclosed |
| US-20110182939-A1 | Vaccine Adjuvants | CADILA PHARMACEUTICALS LTD. (IN) | 2011-07-28 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2284176-A1 | Process for preparing guggulsterones and guggulsterol | Seoul National University Industry Foundation (KR) | 2011-02-16 | — | — | EP | disclosed |
| EP-2251346-A2 | Process for preparing guggulsterones and guggulsterol | Seoul National University Industry Foundation (KR) | 2010-11-17 | — | — | EP | disclosed |
| US-20100240628-A1 | SKIN TREATMENTS | CONOPCO, INC., D/B/A UNILEVER (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2010003696-A2 | BONE IMPLANT APPLICATION | NOBEL BIOCARE SERVICES AG (CH) | 2010-01-14 | — | — | WO | disclosed |
| EP-2143451-A1 | Bone implant application | Nobel Biocare Services AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| EP-1620455-A4 | PROCESS FOR PREPARING GUGGULSTERONES AND GUGGULSTEROL | SEOUL NAT UNIV IND FOUNDATION (KR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2054065-A2 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017692-A2 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2008-02-14 | — | — | WO | disclosed |
| EP-1886685-A1 | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-02-13 | — | — | EP | disclosed |
| EP-1865929-A2 | DIINDOLYLMETHANE-BASED COMPOSITIONS AND METHODS OF USE THEREOF FOR PROMOTING ORAL MUCOSAL AND BONE HEALTH | Bioresponse, L.L.C. (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1423370-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1423111-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-20070055072-A1 | Process for preparing guggulsterones and guggulsterol | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-03-08 | — | — | US | disclosed |
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010501-A1 | Skin treatments | CONOPCO, INC., D/B/A UNILEVER | 2007-01-11 | — | — | US | disclosed |
| US-20060264497-A1 | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health | BIORESPONSE, L.L.C. | 2006-11-23 | — | — | US | disclosed |
| WO-2006105196-A2 | DIINDOLYLMETHANE-BASED COMPOSITIONS AND METHODS OF USE THEREOF FOR PROMOTING ORAL MUCOSAL AND BONE HEALTH | BIORESPONSE, L.L.C. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-7098336-B2 | FXR NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2006-08-29 | — | — | US | disclosed |
| EP-1627030-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2006017211-A1 | GUGGULSTERONE AS AN INHIBITOR OF NUCLEAR FACTOR-KB AND IKBALPHA KINASE ACTIVATION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1624853-A2 | SKIN TREATMENTS | Unilever Plc (GB) | 2006-02-15 | — | — | EP | disclosed |
| EP-1620455-A1 | PROCESS FOR PREPARING GUGGULSTERONES AND GUGGULSTEROL | Kang, Heonjoong (KR) | 2006-02-01 | — | — | EP | disclosed |
| US-20060019907-A1 | Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050085452-A1 | Process for the synthesis of pharmacologically active (z/e)-guggulsterones | LAILA IMPEX (IN) | 2005-04-21 | — | — | US | disclosed |
| US-20050085452-A1 | Process for the synthesis of pharmacologically active (z/e)-guggulsterones | LAILA IMPEX (IN) | 2005-04-21 | — | — | US | disclosed |
| WO-2004104143-A1 | NITROGEN REJECTION FROM CONDENSED NATURAL GAS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103376-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103320-A2 | SKIN TREATMENTS | UNILEVER PLC (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004094450-A1 | PROCESS FOR PREPARING GUGGULSTERONES AND GUGGULSTEROL | KANG HEONJOONG (KR) | 2004-11-04 | — | — | WO | disclosed |
| EP-1432399-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| EP-1423370-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION Bioscience AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1423111-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION Bioscience AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| WO-2004021975-A3 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF PHARMACOLOGICALLY ACTIVE (Z/E)-GUGGULSTERONES | GOKARAJU GANGA RAJU (IN) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004021975-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF PHARMACOLOGICALLY ACTIVE (Z/E)-GUGGULSTERONES | GOKARAJU GANGA RAJU (IN) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004021975-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF PHARMACOLOGICALLY ACTIVE (Z/E)-GUGGULSTERONES | GOKARAJU GANGA RAJU (IN) | 2004-03-18 | — | — | WO | disclosed |
| US-20030130296-A1 | FXR NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2003-07-10 | — | — | US | disclosed |
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC | 2003-07-03 | — | — | US | disclosed |
| WO-2003030857-A1 | ENHANCING EPIDERMAL BARRIER DEVELOPMENT IN SKIN | UNILEVER PLC (GB) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003015771-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015771-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016288-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016280-A1 | NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | SMN1; SMN2 641/4885HSD17B10 1782/4885ALDH1A1 730/4885 |
| US-20050085452-A1 | Process for the synthesis of pharmacologically active (z/e)-guggulsterones | CYP17A1, CYP11B1, HSD17B7 | SMN1; SMN2 4563/4885HSD17B10 51/4885ALDH1A1 626/4885 |
| US-20110182939-A1 | Vaccine Adjuvants | FXR2, FXR1, NR1H4 | SMN1; SMN2 4846/4885HSD17B10 974/4885ALDH1A1 4615/4885 |
| US-20060264497-A1 | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health | HPGDS, IDO1, IDO2 | SMN1; SMN2 3625/4885HSD17B10 2992/4885ALDH1A1 2982/4885 |
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4595/4885HSD17B10 520/4885ALDH1A1 2359/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | SMN1; SMN2 641/4885HSD17B10 1782/4885ALDH1A1 730/4885 |
| US-20070010501-A1 | Skin treatments | RXRG, NR1H2, RXRA | SMN1; SMN2 4711/4885HSD17B10 241/4885ALDH1A1 792/4885 |
| US-20030130296-A1 | FXR NR1H4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4812/4885HSD17B10 609/4885ALDH1A1 3358/4885 |
| US-20100172870-A1 | METHODS, USES AND COMPOSITIONS FOR MODULATING REPLICATION OF HCV THROUGH THE FARNESOID X RECEPTOR (FXR) ACTIVATION OR INHIBITION | FXR1, FXR2, NR1H4 | SMN1; SMN2 4801/4885HSD17B10 457/4885ALDH1A1 4283/4885 |
| US-20030124159-A1 | Enhancing epidermal barrier development in skin | NR1H2, NR1H3, RXRB | SMN1; SMN2 4529/4885HSD17B10 760/4885ALDH1A1 3662/4885 |
| US-10456344-B2 | Hair composition | GLS2, GLS, LHCGR | SMN1; SMN2 4563/4885HSD17B10 321/4885ALDH1A1 2720/4885 |
| US-20070055072-A1 | Process for preparing guggulsterones and guggulsterol | CYP17A1, CYP46A1, HSD17B7 | SMN1; SMN2 4445/4885HSD17B10 48/4885ALDH1A1 2327/4885 |
| US-20100240628-A1 | SKIN TREATMENTS | RXRG, NR1H2, RXRA | SMN1; SMN2 4711/4885HSD17B10 241/4885ALDH1A1 792/4885 |
| US-20170360673-A1 | HAIR COMPOSITION | GLS2, GLS, CYP17A1 | SMN1; SMN2 4613/4885HSD17B10 295/4885ALDH1A1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.